Fighting Bacteria With Its Own Weaponry?
To the Editor:
For many years, intrapleural administration of fi brinolytics and deoxyribonuclease (DNase) was a controversial issue in the management of complicated parapneumonic eff usion and empyema. 1 Th eir eff ectiveness was assessed in a large clinical trial (the second Multicenter Intrapleural Sepsis Trial) . 2 Coadministration of tissue plasminogen activator and DNase was benefi cial in terms of radiographic progression, days of hospitalization, and surgical referral. Instead, DNase alone increased the need for surgery. 2 Th e rationale behind DNase use was to facilitate eff usion drainage via chest tube. So why did DNase monotherapy lead to an unfavorable outcome? First, the main pathogens detected in pleural infections (the Streptococcus milleri group, Staphylococcus aureus , Streptococcus pneumoniae ) encode DNases in their genomes. Th ose nucleases are emerging as potential virulence factors, due to their ability to degrade neutrophil extracellular traps (NETs). 3 Released from neutrophils, NETs, composed mainly of chromatin and certain proteins, entrap and kill bacteria extracellularly. Furthermore, those weblike structures are in abundance in pus, 4 thus, their disassembly may explain the appreciable viscosity reduction aft er DNase treatment. Another issue is the DNases' biofi lm-dispersing activity. Indeed, DNases have been reported to degrade biofi lms, 5 but their role in acute infections is an open question. To refi ne our therapeutic strategies, the exact nature of the tissue plasminogen activator-DNase synergism and NETs disruption impact on clinical course are areas in which further insight must be gained.
Response

To the Editor:
We would like to thank Dr Ntelios for his letter regarding the point/counterpoint editorial discussion on the treatment in pleural infection. 1 Dr Ntelios discusses the potential mechanisms of combined intrapleural fi brinolytics and deoxyribonuclease (DNase) therapy in improving drainage in pleural infection and the potential causes of DNase monotherapy in increasing the need for surgical referral.
Th e second Multicenter Intrapleural Sepsis Trial (MIST2) study results demonstrated effi cacy for improving radiographically measured pleural drainage with the combination of intrapleural tissue plasminogen activator (tPA) and DNase, whereas the agents given alone had no signifi cant eff ect over placebo for the primary outcome measure. 2 In the fi rst MIST study, fi brinolytics alone were shown to have no signifi cant eff ect over placebo. 3 We assume that this is related to a combination of septation disruption and a DNase eff ect that could be related to either viscosity changes or treatment of intrapleural biofi lms, although the exact mechanism is unclear.
DNase alone had negative eff ects on pleural infection, and this may be a clue about the mechanism of action. In MIST2, the need for surgical intervention was increased with DNase alone, and in parallel, there was a nonsignifi cant trend toward increased fever in the DNase-alone group. 2 Th is is in contrast to the result seen
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with combination tPA and DNase in which there was a statistically signifi cant reduction in the need for surgery and a statistically signifi cant reduction in the odds of fever by day 3 compared with placebo. Although these were secondary outcome measures and should, therefore, be treated with some caution, one possible explanation for this result is that DNase alone liberated bacteria (eg, from biofi lms), but in the absence of an agent to improve pleural drainage (ie, a fi brinolytic), this resulted in increased systemic sepsis. Th e eff ect of DNase alone on neutrophil extracellular traps would also be a reasonable potential mechanism. Within the MIST2 study, 2 we specifi ed that surgical intervention should occur in response to both ongoing pleural collection and markers of systemic sepsis aft er treatment (eg, raised infl ammatory markers and fever), and this might explain the negative eff ects of DNase alone on the surgical outcome. We agree that further translational work is now required to elucidate the interactions of tPA, DNase, and the pleural infection microenvironment, which create the signifi cant clinical results seen in MIST2.
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